Evidence map›Paper›PMID 34879065›Full record

ArticlePLoS biology2021

A structurally conserved site in AUP1 binds the E2 enzyme UBE2G2 and is essential for ER-associated degradation.

Christopher E Smith, Yien Che Tsai, Yu-He Liang, Domarin Khago, Jennifer Mariano, Jess Li, Sergey G Tarasov, Emma Gergel, Borong Tsai, Matthew Villaneuva and 6 more

Open access · goldAbstract read
In one paragraph

Article in PLoS biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Christopher E SmithLaboratory of Protein Dynamics and Signaling, Center for Cancer Research, NCI, National Institutes of Health, Frederick, Maryland, United States of America.ORCID 0000-0003-0820-0341
Yien Che TsaiLaboratory of Protein Dynamics and Signaling, Center for Cancer Research, NCI, National Institutes of Health, Frederick, Maryland, United States of America.ORCID 0000-0001-9624-1092
Yu-He LiangCenter for Structural Biology, Center for Cancer Research, NCI, National Institutes of Health, Frederick, Maryland, United States of America.ORCID 0000-0002-0574-2041
Domarin KhagoCenter for Structural Biology, Center for Cancer Research, NCI, National Institutes of Health, Frederick, Maryland, United States of America.
Jennifer MarianoLaboratory of Protein Dynamics and Signaling, Center for Cancer Research, NCI, National Institutes of Health, Frederick, Maryland, United States of America.
Jess LiCenter for Structural Biology, Center for Cancer Research, NCI, National Institutes of Health, Frederick, Maryland, United States of America.ORCID 0000-0001-7708-8555
Sergey G TarasovCenter for Structural Biology, Center for Cancer Research, NCI, National Institutes of Health, Frederick, Maryland, United States of America.
Emma GergelLaboratory of Protein Dynamics and Signaling, Center for Cancer Research, NCI, National Institutes of Health, Frederick, Maryland, United States of America.ORCID 0000-0001-5003-4944
Borong TsaiLaboratory of Protein Dynamics and Signaling, Center for Cancer Research, NCI, National Institutes of Health, Frederick, Maryland, United States of America.
Matthew VillaneuvaLaboratory of Protein Dynamics and Signaling, Center for Cancer Research, NCI, National Institutes of Health, Frederick, Maryland, United States of America.ORCID 0000-0002-5770-2332
Michelle E ClappGenome Modification Core, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America.
Valentin MagidsonOptical Microscopy and Analysis Laboratory, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America.ORCID 0000-0002-0780-9123
Raj ChariGenome Modification Core, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America.
R Andrew ByrdCenter for Structural Biology, Center for Cancer Research, NCI, National Institutes of Health, Frederick, Maryland, United States of America.ORCID 0000-0003-3625-4232
Xinhua JiCenter for Structural Biology, Center for Cancer Research, NCI, National Institutes of Health, Frederick, Maryland, United States of America.ORCID 0000-0001-6942-1514
Allan M WeissmanLaboratory of Protein Dynamics and Signaling, Center for Cancer Research, NCI, National Institutes of Health, Frederick, Maryland, United States of America.ORCID 0000-0002-7865-7702
National Institutes of Health · USFrederick National Laboratory for Cancer Research · US

Funding

Biomolecular Structure and Mechanism, Structure-Based Drug DesignZIABC010326 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI JI, XINHUA · 2009 to 2024
$27.3M
Enzymes and Substrates of the Ubiquitin Conjugating SystemZIABC010292 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WEISSMAN, ALLAN M · 2009 to 2024
$12.2M
Investigation of Protein-Protein Interactions in the ERAD Ubiquitylation PathwayZIABC011131 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI BYRD, ROBERT · 2009 to 2024
$12.0M
CCR NIH HHS HHSN261200800001CIntramural NIH HHS ZIA BC010292Intramural NIH HHS ZIA BC010326Intramural NIH HHS ZIA BC011131NCI NIH HHS HHSN261200800001E
6 · The paper itself

Abstract

Endoplasmic reticulum-associated degradation (ERAD) is a protein quality control pathway of fundamental importance to cellular homeostasis. Although multiple ERAD pathways exist for targeting topologically distinct substrates, all pathways require substrate ubiquitination. Here, we characterize a key role for the UBE2G2 Binding Region (G2BR) of the ERAD accessory protein ancient ubiquitous protein 1 (AUP1) in ERAD pathways. This 27-amino acid (aa) region of AUP1 binds with high specificity and low nanomolar affinity to the backside of the ERAD ubiquitin-conjugating enzyme (E2) UBE2G2. The structure of the AUP1 G2BR (G2BRAUP1) in complex with UBE2G2 reveals an interface that includes a network of salt bridges, hydrogen bonds, and hydrophobic interactions essential for AUP1 function in cells. The G2BRAUP1 shares significant structural conservation with the G2BR found in the E3 ubiquitin ligase gp78 and in vitro can similarly allosterically activate ubiquitination in conjunction with ERAD E3s. In cells, AUP1 is uniquely required to maintain normal levels of UBE2G2; this is due to G2BRAUP1 binding to the E2 and preventing its rapid degradation. In addition, the G2BRAUP1 is required for both ER membrane recruitment of UBE2G2 and for its activation at the ER membrane. Thus, by binding to the backside of a critical ERAD E2, G2BRAUP1 plays multiple critical roles in ERAD.

Indexed as

Amino Acid SequenceCell Line, TumorEndoplasmic ReticulumEndoplasmic Reticulum-Associated DegradationHumansMembrane ProteinsProtein BindingProtein DomainsUbiquitinationUbiquitin-Conjugating EnzymesAUP1 protein, humanMembrane ProteinsUBE2G2 protein, humanUbiquitin-Conjugating Enzymes

Identifiers

PMID34879065
PMCPMC8699718
OpenAlexW4200280904

What Socratic holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.